The purpose of this study was to assess whether MR contrast-enhancement in healthy stromal tissue of the breast is able to further stratify survival of patients considered to be at high risk according to prognostic models derived from the tumor. In 415 patients with pathology proven unilateral invasive ER+HER2- breast cancer, the contralateral parenchymal enhancement was automatically extracted. Contralateral parenchymal enhancement appears to complement existing prognostic models derived from the tumor. In patients at high risk according to conventional prognostic models or molecular assays, contralateral parenchymal enhancement was able identify a subgroup with a relative good survival.
This abstract and the presentation materials are available to members only; a login is required.